Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926.
Douglas M DahlJoseph P RodgersWilliam U ShipleyM Dror MichaelsonChin-Lee WuWilliam ParkerAshesh B JaniFabio L CuryRichard S HudesJeff M MichalskiAlan C HartfordDaniel SongDeborah E CitrinTheodore G KarrisonHoward M SandlerFelix Y FengJason Alexander EfstathiouPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Trimodality therapy is an effective potential alternative to radical cystectomy for recurrent high-grade T1 urothelial cancer of the bladder. At 3 years, 88% of the patients remained free of cystectomy.
Keyphrases
- high grade
- phase ii
- low grade
- end stage renal disease
- clinical trial
- spinal cord injury
- newly diagnosed
- chronic kidney disease
- open label
- urinary tract
- randomized controlled trial
- papillary thyroid
- peritoneal dialysis
- prognostic factors
- squamous cell carcinoma
- neoadjuvant chemotherapy
- muscle invasive bladder cancer
- radiation therapy
- placebo controlled
- mesenchymal stem cells
- young adults
- minimally invasive
- phase iii
- locally advanced
- smoking cessation
- patient reported